Teva/Novopharm merger update
Teva has signed a letter of intent to acquire the privately-held Canadian generic firm Novopharm, Ltd. for 4.8 mil. shares of Teva common stock (valued at approximately $264 mil.). However, completion of the agreement awaits "the resolution to Teva's satisfaction of certain issues now pending before a Canadian court relating to the scope and duration of an existing injunction against Novopharm." Teva is "hopeful that a court decision will be rendered within the next few months"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth